Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Analytical evaluation of point-of-care procalcitonin (PCT) and clinical performances in an unselected population as compared with central lab PCT assay

Analytical evaluation of point-of-care procalcitonin (PCT) and clinical performances in an... To the Editor,Procalcitonin (PCT) is well established as a biomarker that reflects the presence and severity of local and systemic bacterial infections, i.e. sepsis [1] and as valuable tool to guide antibiotic treatment [2], [3] allowing to tailor antibiotic treatment and to reduce antibiotic resistance [4]. PCT is widely used as a rule-out test for sepsis and it is frequently requested by primary care doctors facilitating a clinician decision. Several studies have shown that specific treatment should ideally be initiated within 4 h and no later than 8 h after diagnosis [5], [6]. Hence, the establishment of a point-of-care (POC) for the determination of the PCT could be of great interest reducing the time to diagnosis for patients with suspected sepsis. To date, only Thermo Fisher has developed a POC (called BRAHMS PCT direct) for fast PCT measurement [7].In recent times, Radiometer launched a POC test for PCT adapted for emergency situations with a low functional sensitivity. Here, we report the analytical performances of the Radiometer AQT90 FLEX® PCT assay (Neuilly-Plaisance, France) and we evaluate the concordance with Elecsys BRAHMS PCT on Cobas8000/e602© (Roche, Meylan, France) and BRAHMS PCT Kryptor Compact Plus© results from central laboratory considered as reference http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Chemistry and Laboratory Medicine (CCLM) de Gruyter

Analytical evaluation of point-of-care procalcitonin (PCT) and clinical performances in an unselected population as compared with central lab PCT assay

Loading next page...
 
/lp/degruyter/analytical-evaluation-of-point-of-care-procalcitonin-pct-and-clinical-3xLbqEJl33
Publisher
de Gruyter
Copyright
©2017 Walter de Gruyter GmbH, Berlin/Boston
ISSN
1437-4331
eISSN
1437-4331
DOI
10.1515/cclm-2016-0887
pmid
27987361
Publisher site
See Article on Publisher Site

Abstract

To the Editor,Procalcitonin (PCT) is well established as a biomarker that reflects the presence and severity of local and systemic bacterial infections, i.e. sepsis [1] and as valuable tool to guide antibiotic treatment [2], [3] allowing to tailor antibiotic treatment and to reduce antibiotic resistance [4]. PCT is widely used as a rule-out test for sepsis and it is frequently requested by primary care doctors facilitating a clinician decision. Several studies have shown that specific treatment should ideally be initiated within 4 h and no later than 8 h after diagnosis [5], [6]. Hence, the establishment of a point-of-care (POC) for the determination of the PCT could be of great interest reducing the time to diagnosis for patients with suspected sepsis. To date, only Thermo Fisher has developed a POC (called BRAHMS PCT direct) for fast PCT measurement [7].In recent times, Radiometer launched a POC test for PCT adapted for emergency situations with a low functional sensitivity. Here, we report the analytical performances of the Radiometer AQT90 FLEX® PCT assay (Neuilly-Plaisance, France) and we evaluate the concordance with Elecsys BRAHMS PCT on Cobas8000/e602© (Roche, Meylan, France) and BRAHMS PCT Kryptor Compact Plus© results from central laboratory considered as reference

Journal

Clinical Chemistry and Laboratory Medicine (CCLM)de Gruyter

Published: Jul 26, 2017

References